Role of Nerve and Muscle Biopsies in Pediatric Patients in the Era of Genetic Testing

Kaili Yang, Susan T Iannaccone, Lorrie S. Burkhalter, Joan S Reisch, Chunyu Cai, David T Schindel

Research output: Contribution to journalArticle

Abstract

Background: An operative biopsy is an important component in the diagnosis and treatment of neuromuscular disorders (NMDs). However, recent advances in molecular genetics suggest less invasive genetic testing should be the initial approach. The purpose of our study was to demonstrate the diagnostic value of muscle or nerve biopsy within the pediatric population at a pediatric academic center and offer recommendations for genetic testing in relation to biopsy to achieve the highest diagnostic yield. Methods: Following institutional review board approval, we retrospectively reviewed the electronic medical record of 221 pediatric patients who underwent muscle and/or nerve biopsy for suspicion of NMD from January 2007 to March 2018. Demographics, family history, clinical presentations, genetic testing results, pathology results, anesthesia complications, clinical diagnoses, and clinic follow-up data were collected. Chi-square analysis was done for statistical significance. Results: A total of 220 underwent muscle biopsy, and 15 underwent nerve biopsy. Not all patients received genetic testing. The average age at biopsy was 7.7 y. Biopsy revealed significant histologic abnormalities in 62.9% (139), directly leading to a specific clinical diagnosis in 33.9% (75). When genetic testing was done before biopsy, definite pathogenic variants were found in 7.6% (9). When genetic testing was done after biopsy, definite pathogenic variants were found in 45.0% (27). Genetic testing yield for pathogenic variants was higher when done after biopsy (P value < 0.00001). Conclusions: Muscle and nerve biopsies may provide significant diagnostic value. Biopsy helped to rule in or out NMD and guide genetic testing. Our data suggest NMD genetic testing yield was higher when done after biopsy.

Original languageEnglish (US)
Pages (from-to)27-32
Number of pages6
JournalJournal of Surgical Research
Volume243
DOIs
StatePublished - Nov 1 2019

Fingerprint

Genetic Testing
Pediatrics
Biopsy
Muscles
Electronic Health Records
Research Ethics Committees
Molecular Biology
Anesthesia

Keywords

  • Genetic testing
  • Muscle biopsy
  • Nerve biopsy
  • Pediatric neuromuscular disorders

ASJC Scopus subject areas

  • Surgery

Cite this

Role of Nerve and Muscle Biopsies in Pediatric Patients in the Era of Genetic Testing. / Yang, Kaili; Iannaccone, Susan T; Burkhalter, Lorrie S.; Reisch, Joan S; Cai, Chunyu; Schindel, David T.

In: Journal of Surgical Research, Vol. 243, 01.11.2019, p. 27-32.

Research output: Contribution to journalArticle

@article{035b0ba5ad6841a4a18495720eac6bb1,
title = "Role of Nerve and Muscle Biopsies in Pediatric Patients in the Era of Genetic Testing",
abstract = "Background: An operative biopsy is an important component in the diagnosis and treatment of neuromuscular disorders (NMDs). However, recent advances in molecular genetics suggest less invasive genetic testing should be the initial approach. The purpose of our study was to demonstrate the diagnostic value of muscle or nerve biopsy within the pediatric population at a pediatric academic center and offer recommendations for genetic testing in relation to biopsy to achieve the highest diagnostic yield. Methods: Following institutional review board approval, we retrospectively reviewed the electronic medical record of 221 pediatric patients who underwent muscle and/or nerve biopsy for suspicion of NMD from January 2007 to March 2018. Demographics, family history, clinical presentations, genetic testing results, pathology results, anesthesia complications, clinical diagnoses, and clinic follow-up data were collected. Chi-square analysis was done for statistical significance. Results: A total of 220 underwent muscle biopsy, and 15 underwent nerve biopsy. Not all patients received genetic testing. The average age at biopsy was 7.7 y. Biopsy revealed significant histologic abnormalities in 62.9{\%} (139), directly leading to a specific clinical diagnosis in 33.9{\%} (75). When genetic testing was done before biopsy, definite pathogenic variants were found in 7.6{\%} (9). When genetic testing was done after biopsy, definite pathogenic variants were found in 45.0{\%} (27). Genetic testing yield for pathogenic variants was higher when done after biopsy (P value < 0.00001). Conclusions: Muscle and nerve biopsies may provide significant diagnostic value. Biopsy helped to rule in or out NMD and guide genetic testing. Our data suggest NMD genetic testing yield was higher when done after biopsy.",
keywords = "Genetic testing, Muscle biopsy, Nerve biopsy, Pediatric neuromuscular disorders",
author = "Kaili Yang and Iannaccone, {Susan T} and Burkhalter, {Lorrie S.} and Reisch, {Joan S} and Chunyu Cai and Schindel, {David T}",
year = "2019",
month = "11",
day = "1",
doi = "10.1016/j.jss.2019.04.085",
language = "English (US)",
volume = "243",
pages = "27--32",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Role of Nerve and Muscle Biopsies in Pediatric Patients in the Era of Genetic Testing

AU - Yang, Kaili

AU - Iannaccone, Susan T

AU - Burkhalter, Lorrie S.

AU - Reisch, Joan S

AU - Cai, Chunyu

AU - Schindel, David T

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Background: An operative biopsy is an important component in the diagnosis and treatment of neuromuscular disorders (NMDs). However, recent advances in molecular genetics suggest less invasive genetic testing should be the initial approach. The purpose of our study was to demonstrate the diagnostic value of muscle or nerve biopsy within the pediatric population at a pediatric academic center and offer recommendations for genetic testing in relation to biopsy to achieve the highest diagnostic yield. Methods: Following institutional review board approval, we retrospectively reviewed the electronic medical record of 221 pediatric patients who underwent muscle and/or nerve biopsy for suspicion of NMD from January 2007 to March 2018. Demographics, family history, clinical presentations, genetic testing results, pathology results, anesthesia complications, clinical diagnoses, and clinic follow-up data were collected. Chi-square analysis was done for statistical significance. Results: A total of 220 underwent muscle biopsy, and 15 underwent nerve biopsy. Not all patients received genetic testing. The average age at biopsy was 7.7 y. Biopsy revealed significant histologic abnormalities in 62.9% (139), directly leading to a specific clinical diagnosis in 33.9% (75). When genetic testing was done before biopsy, definite pathogenic variants were found in 7.6% (9). When genetic testing was done after biopsy, definite pathogenic variants were found in 45.0% (27). Genetic testing yield for pathogenic variants was higher when done after biopsy (P value < 0.00001). Conclusions: Muscle and nerve biopsies may provide significant diagnostic value. Biopsy helped to rule in or out NMD and guide genetic testing. Our data suggest NMD genetic testing yield was higher when done after biopsy.

AB - Background: An operative biopsy is an important component in the diagnosis and treatment of neuromuscular disorders (NMDs). However, recent advances in molecular genetics suggest less invasive genetic testing should be the initial approach. The purpose of our study was to demonstrate the diagnostic value of muscle or nerve biopsy within the pediatric population at a pediatric academic center and offer recommendations for genetic testing in relation to biopsy to achieve the highest diagnostic yield. Methods: Following institutional review board approval, we retrospectively reviewed the electronic medical record of 221 pediatric patients who underwent muscle and/or nerve biopsy for suspicion of NMD from January 2007 to March 2018. Demographics, family history, clinical presentations, genetic testing results, pathology results, anesthesia complications, clinical diagnoses, and clinic follow-up data were collected. Chi-square analysis was done for statistical significance. Results: A total of 220 underwent muscle biopsy, and 15 underwent nerve biopsy. Not all patients received genetic testing. The average age at biopsy was 7.7 y. Biopsy revealed significant histologic abnormalities in 62.9% (139), directly leading to a specific clinical diagnosis in 33.9% (75). When genetic testing was done before biopsy, definite pathogenic variants were found in 7.6% (9). When genetic testing was done after biopsy, definite pathogenic variants were found in 45.0% (27). Genetic testing yield for pathogenic variants was higher when done after biopsy (P value < 0.00001). Conclusions: Muscle and nerve biopsies may provide significant diagnostic value. Biopsy helped to rule in or out NMD and guide genetic testing. Our data suggest NMD genetic testing yield was higher when done after biopsy.

KW - Genetic testing

KW - Muscle biopsy

KW - Nerve biopsy

KW - Pediatric neuromuscular disorders

UR - http://www.scopus.com/inward/record.url?scp=85066247316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066247316&partnerID=8YFLogxK

U2 - 10.1016/j.jss.2019.04.085

DO - 10.1016/j.jss.2019.04.085

M3 - Article

C2 - 31151034

AN - SCOPUS:85066247316

VL - 243

SP - 27

EP - 32

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

ER -